Literature DB >> 20658599

Signs and symptoms versus nerve conduction studies to diagnose diabetic sensorimotor polyneuropathy: Cl vs. NPhys trial.

Peter J Dyck1, Carol J Overland, Phillip A Low, William J Litchy, Jenny L Davies, P James B Dyck, Peter C O'Brien, James W Albers, Henning Andersen, Charles F Bolton, John D England, Christopher J Klein, J Gareth Llewelyn, Michelle L Mauermann, James W Russell, Wolfgang Singer, A Gordon Smith, Solomon Tesfaye, Adrian Vella.   

Abstract

The purpose was to test whether physicians can validly and reproducibly diagnose diabetic sensorimotor polyneuropathy (DSPN). Twelve physicians assessed 24 patients with diabetes mellitus (DM) on consecutive days (576 examinations) with physical features and voice disguised. Results were compared to gold standard 75% group diagnosis (dx) and a nerve conduction score (Sigma5 NC nds). Masking of patients was achieved. Reproducibility measured by the kappa coefficient and compared to Sigma5 NC nd varied considerably among physicians: median and ranges: signs 0.8 (0.32-1.0); symptoms 0.79 (0.36-1.0), and diagnoses 0.47 (0.33-0.84), both low and high scores indicating poor performance. There was substantial agreement between 75% group dx and confirmed NC abnormality (abn). As compared to Sigma5 NC, individual physicians' clinical dx was excessively variable and frequently inaccurate. Study physician dx from signs and symptoms were excessively variable, often overestimating DSPN. Specific approaches to improving clinical proficiency should be tested.

Entities:  

Mesh:

Year:  2010        PMID: 20658599      PMCID: PMC2956592          DOI: 10.1002/mus.21661

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  18 in total

1.  Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies.

Authors:  D N Herrmann; J W Griffin; P Hauer; D R Cornblath; J C McArthur
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

2.  Quantitative sensory testing: a consensus report from the Peripheral Neuropathy Association.

Authors: 
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

3.  Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group.

Authors:  D A Greene; J C Arezzo; M B Brown
Journal:  Neurology       Date:  1999-08-11       Impact factor: 9.910

4.  F-wave latency serves as the most reproducible measure in nerve conduction studies of diabetic polyneuropathy: multicentre analysis in healthy subjects and patients with diabetic polyneuropathy.

Authors:  N Kohara; J Kimura; R Kaji; Y Goto; J Ishii; M Takiguchi; M Nakai
Journal:  Diabetologia       Date:  2000-07       Impact factor: 10.122

5.  The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests.

Authors:  P J Dyck; K M Kratz; K A Lehman; J L Karnes; L J Melton; P C O'Brien; W J Litchy; A J Windebank; B E Smith; P A Low
Journal:  Neurology       Date:  1991-06       Impact factor: 9.910

6.  Electrophysiological studies in diabetic neuropathy.

Authors:  A Lamontagne; F Buchthal
Journal:  J Neurol Neurosurg Psychiatry       Date:  1970-08       Impact factor: 10.154

7.  The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study.

Authors:  P J Dyck; K M Kratz; J L Karnes; W J Litchy; R Klein; J M Pach; D M Wilson; P C O'Brien; L J Melton; F J Service
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

Review 8.  Detection, characterization, and staging of polyneuropathy: assessed in diabetics.

Authors:  P J Dyck
Journal:  Muscle Nerve       Date:  1988-01       Impact factor: 3.217

9.  Individual attributes versus composite scores of nerve conduction abnormality: sensitivity, reproducibility, and concordance with impairment.

Authors:  Peter J Dyck; William J Litchy; Jasper R Daube; C Michel Harper; P James B Dyck; Jenny Davies; Peter C O'Brien
Journal:  Muscle Nerve       Date:  2003-02       Impact factor: 3.217

10.  Variables influencing neuropathic endpoints: the Rochester Diabetic Neuropathy Study of Healthy Subjects.

Authors:  P J Dyck; W J Litchy; K A Lehman; J L Hokanson; P A Low; P C O'Brien
Journal:  Neurology       Date:  1995-06       Impact factor: 9.910

View more
  74 in total

1.  Multicenter trial of the proficiency of smart quantitative sensation tests.

Authors:  Peter J Dyck; Barbara Argyros; James W Russell; Linde E Gahnstrom; Susan Nalepa; James W Albers; Karen A Lodermeier; Andrew J Zafft; P James B Dyck; Christopher J Klein; William J Litchy; Jenny L Davies; Rickey E Carter; L Joseph Melton
Journal:  Muscle Nerve       Date:  2014-01-28       Impact factor: 3.217

Review 2.  Diabetic neuropathy: mechanisms, emerging treatments, and subtypes.

Authors:  James W Albers; Rodica Pop-Busui
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 3.  Corneal confocal microscopy to assess diabetic neuropathy: an eye on the foot.

Authors:  Mitra Tavakoli; Ioannis N Petropoulos; Rayaz A Malik
Journal:  J Diabetes Sci Technol       Date:  2013-09-01

4.  Longitudinal assessment of oxaliplatin-induced neuropathy.

Authors:  A Z Burakgazi; W Messersmith; D Vaidya; P Hauer; A Hoke; Michael Polydefkis
Journal:  Neurology       Date:  2011-08-24       Impact factor: 9.910

5.  Small nerve fiber quantification in the diagnosis of diabetic sensorimotor polyneuropathy: comparing corneal confocal microscopy with intraepidermal nerve fiber density.

Authors:  Xin Chen; Jim Graham; Mohammad A Dabbah; Ioannis N Petropoulos; Georgios Ponirakis; Omar Asghar; Uazman Alam; Andrew Marshall; Hassan Fadavi; Maryam Ferdousi; Shazli Azmi; Mitra Tavakoli; Nathan Efron; Maria Jeziorska; Rayaz A Malik
Journal:  Diabetes Care       Date:  2015-03-20       Impact factor: 19.112

6.  Diagnostic performance of two-dimensional shear wave elastography for evaluating tibial nerve stiffness in patients with diabetic peripheral neuropathy.

Authors:  Weixi Jiang; Sirun Huang; Hua Teng; Peipei Wang; Meng Wu; Xia Zhou; Weiwei Xu; Qunxia Zhang; Haitao Ran
Journal:  Eur Radiol       Date:  2018-11-28       Impact factor: 5.315

Review 7.  Office immunotherapy in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.

Authors:  Peter J Dyck; Bruce V Taylor; Jenny L Davies; Michelle L Mauermann; William J Litchy; Christopher J Klein; P James B Dyck
Journal:  Muscle Nerve       Date:  2015-08-13       Impact factor: 3.217

8.  "Unequivocally Abnormal" vs "Usual" Signs and Symptoms for Proficient Diagnosis of Diabetic Polyneuropathy: Cl vs N Phys Trial.

Authors:  Peter J Dyck; Carol J Overland; Phillip A Low; William J Litchy; Jenny L Davies; P James B Dyck; Rickey E Carter; L Joseph Melton; Henning Andersen; James W Albers; Charles F Bolton; John D England; Christopher J Klein; Gareth Llewelyn; Michelle L Mauermann; James W Russell; Dinesh Selvarajah; Wolfgang Singer; A Gordon Smith; Solomon Tesfaye; Adrian Vella
Journal:  Arch Neurol       Date:  2012-12

9.  Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial.

Authors:  Peter J Dyck; John C Kincaid; P James B Dyck; Vinay Chaudhry; Namita A Goyal; Christina Alves; Hayet Salhi; Janice F Wiesman; Celine Labeyrie; Jessica Robinson-Papp; Márcio Cardoso; Matilde Laura; Katherine Ruzhansky; Andrea Cortese; Thomas H Brannagan; Julie Khoury; Sami Khella; Márcia Waddington-Cruz; João Ferreira; Annabel K Wang; Marcus V Pinto; Samar S Ayache; Merrill D Benson; John L Berk; Teresa Coelho; Michael Polydefkis; Peter Gorevic; David H Adams; Violaine Plante-Bordeneuve; Carol Whelan; Giampaolo Merlini; Stephen Heitner; Brian M Drachman; Isabel Conceição; Christopher J Klein; Morie A Gertz; Elizabeth J Ackermann; Steven G Hughes; Michelle L Mauermann; Rito Bergemann; Karen A Lodermeier; Jenny L Davies; Rickey E Carter; William J Litchy
Journal:  Muscle Nerve       Date:  2017-04-07       Impact factor: 3.217

10.  Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

Authors:  Phillip A Low; David Robertson; Sid Gilman; Horacio Kaufmann; Wolfgang Singer; Italo Biaggioni; Roy Freeman; Susan Perlman; Robert A Hauser; William Cheshire; Stephanie Lessig; Steven Vernino; Jay Mandrekar; William D Dupont; Thomas Chelimsky; Wendy R Galpern
Journal:  Lancet Neurol       Date:  2014-02-05       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.